Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years – PROTECT Cohort, July 2021-February 2022

On March 11, 2022, this report was posted online as an MMWR Early Release.

Ashley L. Fowlkes, ScD1; Sarang K. Yoon, DO2; Karen Lutrick, PhD3; Lisa Gwynn, DO4; Joy Burns, PhD5; Lauren Grant, MS1; Andrew L. Phillips, MD2; Katherine Ellingson, PhD6; Maria V. Ferraris, MEd, MSPM4; Lindsay B. LeClair, MS, MPH5; Clare Mathenge7; Young M. Yoo, MSPH1; Matthew S. Thiese, PhD2; Lynn B. Gerald, PhD6; Natasha Schaefer Solle, PhD4; Zuha Jeddy, MPH5; Leah Odame-Bamfo, MPH7; Josephine Mak, MPH1; Kurt T. Hegmann, MD2; Joe K. Gerald, MD6; Jezahel S. Ochoa4; Mark Berry, PhD5; Spencer Rose7; Julie Mayo Lamberte, MSPH1; Purnima Madhivanan, MBBS6; Felipe A. Pubillones, DO4; Ramona P. Rai, MPH5; Kayan Dunnigan, MPH7; John T. Jones, MSPH1; Karl Krupp, PhD6; Laura J. Edwards, MPH5; Edward J. Bedrick, PhD6; Brian E. Sokol, MSPA5; Ashley Lowe, PhD6; Hilary McLeland-Wieser, MPH5; Krystal S. Jovel, MA6; Deanna E. Fleary, MSc5; Sana M. Khan, MPH6; Brandon Poe, MPA5; James Hollister6; Joanna Lopez, MSPH5; Patrick Rivers, MPP3; Shawn Beitel, MSc6; Harmony L. Tyner, MD8; Allison L. Naleway, PhD9; Lauren E.W. Olsho, PhD5; Alberto J. Caban-Martinez, DO, PhD4; Jefferey L. Burgess, MD6; Mark G. Thompson, PhD1; Manjusha Gaglani, MBBS7,1

Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn